Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness

Table 1 Characteristics of the individual patients

No.	Age (yr)	Sex	ECOG PS	Primary tumor	Site of metastases	Liver metastases	RAS and BRAF mutation	Lines of treatment	Prior 5-Fu	Prior platinum	Prior irinotecan	Prior bevacizumab	Prior cetuximab	Prior regorafenib	Prior PD-1
1	56	Female	1	Sigmoid colon	Abdominal metastases	No	Wild-type	3	Yes	Yes	Yes	Yes	Yes	No	No
2	62	Female	3	Ascending colon	Multiple metastases	Yes	Not tested	4	Yes	Yes	Yes	Yes	No	Yes	No
3	51	Female	0	Rectum	Multiple metastases	Yes	Not tested	3	Yes	Yes	Yes	Yes	No	No	No
4	52	Female	1	Sigmoid colon	Multiple metastases	No	KRAS mutation	3	Yes	Yes	Yes	Yes	No	No	No
5	66	Female	1	Ascending colon	Multiple metastases	Yes	Not tested	4	Yes	Yes	Yes	Yes	No	Yes	No
6	57	Female	2	Sigmoid colon	Multiple metastases	No	Wild-type	3	Yes	Yes	Yes	Yes	Yes	No	No
7	48	Female	3	Liver curvature of the transverse colon	Multiple metastases	Yes	Not tested	3	Yes	Yes	Yes	Yes	No	No	No
8	61	Female	2	Rectum	Pelvic metastases	No	KRAS mutation	3	Yes	Yes	Yes	Yes	No	No	No
9	65	Female	1	Rectum	Ovary metastases	No	Wild-type	4	Yes	Yes	Yes	Yes	Yes	Yes	No
10	65	Female	0	Ascending colon	Lung metastases	No	Not tested	3	Yes	Yes	Yes	Yes	No	No	No
11	56	Female	2	Left half of the colon	Ovary metastases	No	Wild-type	3	Yes	Yes	Yes	Yes	Yes	No	No
12	27	Male	0	Sigmoid colon	Pelvic metastases	No	Wild-type	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes
13	58	Male	1	Sigmoid colon	Liver metastases	Yes	Not tested	3	Yes	Yes	Yes	Yes	No	No	No
14	70	Female	1	Rectum	Lung metastases	No	Not tested	4	Yes	Yes	Yes	Yes	No	No	No
15	54	Male	1	Ascending colon	Multiple metastases	Yes	KRAS mutation	3	Yes	Yes	Yes	Yes	No	No	No
16	55	Male	1	Rectum	Multiple metastases	Yes	NRAS mutation	4	Yes	Yes	Yes	Yes	No	Yes	No
17	48	Female	0	Rectum	Multiple metastases	Yes	Wild-type	3	Yes	Yes	Yes	Yes	Yes	No	No
18	55	Male	1	Rectum	Multiple metastases	Yes	Wild-type	3	Yes	Yes	Yes	Yes	Yes	No	No
19	64	Male	2	Rectum	Multiple metastases	Yes	KRAS mutation	3	Yes	Yes	Yes	Yes	No	No	No
20	58	Female	0	Ascending colon	Multiple metastases	Yes	Wild-type	3	Yes	Yes	Yes	Yes	Yes	No	No
21	44	Female	2	Sigmoid colon	Multiple metastases	Yes	Wild-type	3	Yes	Yes	Yes	Yes	Yes	No	No
22	51	Male	1	Rectum	Multiple metastases	Yes	Not tested	4	Yes	Yes	Yes	Yes	No	Yes	No
23	56	Male	1	Rectum	Lung metastases	No	Not tested	4	Yes	Yes	Yes	Yes	No	No	No
24	61	Male	2	Rectum	Multiple metastases	Yes	Not tested	4	Yes	Yes	Yes	Yes	No	No	No
25	73	Male	0	Rectum	Multiple metastases	Yes (radiofrequency)	Wild-type	3	Yes	Yes	Yes	Yes	Yes	No	No
26	61	Male	1	Rectum	Multiple metastases	Yes	Wild-type	4	Yes	Yes	Yes	Yes	Yes	Yes	No
27	58	Male	2	Sigmoid colon	Multiple metastases	No	KRAS mutation	3	Yes	Yes	Yes	Yes	No	No	No
28	57	Female	1	Sigmoid colon	Liver metastases	Yes (hepatectomy)	KRAS mutation	3	Yes	Yes	Yes	Yes	No	No	No
29	67	Male	2	Rectum	Liver metastases	Yes	Not tested	3	Yes	Yes	Yes	Yes	No	No	No
30	61	Male	1	Sigmoid colon	Peritoneal metastasis	No	Wide-type	3	Yes	Yes	Yes	Yes	Yes	No	No

ECOG PS: Eastern Cooperative Oncology Group performance status.